Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 7/10/2025

Hypertension Management

Introduction to Guideline Recommendations

  • The European Society of Cardiology recommends combining a RAS blocker (like losartan) with a dihydropyridine CCB (like amlodipine) as a preferred combination for hypertension management in patients with CKD stage 3b, providing complementary mechanisms for blood pressure control while offering renoprotective benefits beyond blood pressure reduction alone 1

Renoprotective Benefits and Treatment Initiation

  • ARBs like losartan have demonstrated clear evidence of reduction in risks for both kidney failure and cardiovascular events in CKD patients with albuminuria, highlighting the importance of initiating treatment with losartan, particularly in patients with albuminuria, as recommended by KDIGO for CKD with albuminuria 2

Blood Pressure Targets and Monitoring

  • The target blood pressure should be 120-129 mmHg systolic, as this target is associated with reduced cardiovascular events and mortality, and if poorly tolerated, aim for "as low as reasonably achievable" (ALARA principle), according to the European Society of Cardiology 1
  • The European Society of Cardiology recommends targeting blood pressure at 120-129 mmHg systolic for most patients 1

Medication Considerations and Adherence

  • Consider fixed-dose combination pills when available to enhance medication adherence, as recommended by the European Society of Cardiology 1
  • The European Society of Cardiology recommends using fixed-dose combination pills when possible to improve adherence 1
  • For most patients requiring additional blood pressure control beyond losartan, a calcium channel blocker (particularly amlodipine) is the recommended first-choice add-on therapy due to complementary mechanisms of action and proven efficacy, as recommended by the European Society of Cardiology 1
  • The American College of Cardiology recommends amlodipine (5-10 mg daily) as a first-choice add-on therapy for patients with hypertension, providing a complementary mechanism of action 3, 1

Special Patient Populations

  • For patients with stage 2 hypertension (BP ≥160/100 mmHg), the American College of Cardiology recommends starting with dual therapy immediately: losartan + amlodipine 3, 1
  • For patients with chronic kidney disease, the American College of Cardiology recommends losartan + thiazide-like diuretic (if eGFR >30 mL/min/1.73m²) or losartan + loop diuretic (if eGFR <30 mL/min/1.73m²) 3, 4
  • For patients with heart failure with reduced ejection fraction, the American College of Cardiology recommends losartan + beta-blocker (e.g., carvedilol, metoprolol succinate) and avoiding non-dihydropyridine CCBs (diltiazem, verapamil) 3, 1
  • For elderly patients, the American College of Cardiology recommends starting with lower doses (amlodipine 2.5 mg) and monitoring closely for orthostatic hypotension, although this specific recommendation is from Praxis Medical Insights, a similar recommendation can be found from other sources 5

Safety Considerations

  • Avoid dual RAS blockade by never combining losartan with an ACE inhibitor due to increased risk of hyperkalemia and acute kidney injury without additional benefit, as advised by the American Journal of Kidney Diseases and Annals of Internal Medicine 4, 2
  • The American College of Cardiology recommends avoiding combinations of ACE inhibitors + losartan (dual RAS blockade) due to increased risk of hyperkalemia and acute kidney injury 3
  • The American College of Cardiology recommends using potassium supplements or potassium-sparing diuretics with caution due to increased risk of hyperkalemia when combined with losartan 3
  • The American College of Cardiology recommends monitoring serum potassium, especially when combining losartan with potassium-sparing agents 3

Medication Administration

  • The European Society of Cardiology recommends considering the timing of medication (morning vs evening) based on patient preference to establish consistent habits 1